Overview

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Treatments:
Cyclophosphamide
Fludarabine
Rituximab
Thymoglobulin